Emerging management of metastatic castration-sensitive prostate cancer: front-line chemotherapy vs. oral therapy

Bookmark and Share
Published: 8 May 2019
Views: 372
Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA

Prof Jorge Garcia speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the management of metastatic castration-sensitive prostate cancer.

Prof Garcia explains the drastic changes in the management of these patients over the past 4 years. Traditionally, the suppression of testosterone combined with sequential therapy has been the standard of care. However, in more recent times, clinicians use these agents in the first instance, rather than to wait until the patient becomes castration-resistant.

He also states the importance of investigating the 'volume of disease' in these patients, which solidified the role of docetaxel-based chemotherapy. However, data from the LATITUDE trial revealed significantly improved outcomes for men with high volume disease who were treated with ADT and abiraterone acetate.

Prof Garcia discusses data from the STAMPEDE trial in which patients with low-volume disease benefitted from ADT, abiraterone acetate and radiotherapy for the primary tumour.